Therapeutic Exploratory Phase 2 Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease(NAFLD) Except Cirrhosis

NCT02029586 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

18

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of recruitment

Conditions

Nonalcoholic Fatty Liver Disease

Interventions

DRUG: MB12066 200mg
DRUG: Placebo

Sponsor

Yungjin Pharm. Co., Ltd.